Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market 2021 by Key Countries, Companies, Type and Application

Q: What are the significant segments operating in the market?

Market is segmented on the basis. Read More

Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market 2021 by Key Countries, Companies, Type and Application

Report ID : 184147
Published On: Mar, 2021
Pages: 156
Pharmaceuticals and Healthcare

Buy @ $3500

The Postmenopausal Vaginal Atrophy (PVA) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Postmenopausal Vaginal Atrophy (PVA) Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Postmenopausal Vaginal Atrophy (PVA) Treatment market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation

Postmenopausal Vaginal Atrophy (PVA) Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Systemic Estrogen Treatments

Non-estrogenic Therapies

Market segment by Application, can be divided into

Hospital

Clinics

Market segment by players, this report covers

EndoCeutics

Upsher-Smith Laboratories

TherapeuticsMD

Bionovo

Pfizer

Novo Nordisk

Allergan

Shionogi

Ligand Pharmaceuticals

Bayer

Pantarhei Bioscience

Foamix Pharmaceuticals

Pep-Tonic Medical

Teva Pharmaceuticals

Market segment by Region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, Spain, Benelux, Nordic, and Rest of Europe)

Asia (China, Japan, Korea, India, Southeast Asia, Australia, China Taiwan, and Rest of Asia)

South America (Brazil, Argentina, and Rest of South America)

MENA (Saudi Arabia, UAE, Turkey, and Rest of EMNA)

Frequently Asked Questions

What is scope of the report?

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

What are the significant segments operating in the market?

Market is segmented on the basis:

By Type
By Application
By Region
By Country
By Manufacturer

What are the vital market dynamics?

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

What does a company profile includes?

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Postmenopausal Vaginal Atrophy (PVA) Treatment

1.2 Classification of Postmenopausal Vaginal Atrophy (PVA) Treatment by Type

1.2.1 Overview: Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share by Type in 2020

1.2.3 Systemic Estrogen Treatments

1.2.4 Non-estrogenic Therapies

1.3 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market by Application

1.3.1 Overview: Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Hospital

1.3.3 Clinics

1.4 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size & Forecast

1.5 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast by Region

1.5.1 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Region, (2016-2026)

1.5.3 North America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Prospect (2016-2026)

1.5.4 Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Prospect (2016-2026)

1.5.5 Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Prospect (2016-2026)

1.5.6 South America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Prospect (2016-2026)

1.5.7 MENA Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Postmenopausal Vaginal Atrophy (PVA) Treatment Market Drivers

1.6.2 Postmenopausal Vaginal Atrophy (PVA) Treatment Market Restraints

1.6.3 Postmenopausal Vaginal Atrophy (PVA) Treatment Trends Analysis

2 Company Profiles

2.1 EndoCeutics

2.1.1 EndoCeutics Details

2.1.2 EndoCeutics Major Business

2.1.3 EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

2.1.4 EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 EndoCeutics Recent Developments and Future Plans

2.2 Upsher-Smith Laboratories

2.2.1 Upsher-Smith Laboratories Details

2.2.2 Upsher-Smith Laboratories Major Business

2.2.3 Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

2.2.4 Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Upsher-Smith Laboratories Recent Developments and Future Plans

2.3 TherapeuticsMD

2.3.1 TherapeuticsMD Details

2.3.2 TherapeuticsMD Major Business

2.3.3 TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

2.3.4 TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 TherapeuticsMD Recent Developments and Future Plans

2.4 Bionovo

2.4.1 Bionovo Details

2.4.2 Bionovo Major Business

2.4.3 Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

2.4.4 Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Bionovo Recent Developments and Future Plans

2.5 Pfizer

2.5.1 Pfizer Details

2.5.2 Pfizer Major Business

2.5.3 Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

2.5.4 Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Pfizer Recent Developments and Future Plans

2.6 Novo Nordisk

2.6.1 Novo Nordisk Details

2.6.2 Novo Nordisk Major Business

2.6.3 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

2.6.4 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 Novo Nordisk Recent Developments and Future Plans

2.7 Allergan

2.7.1 Allergan Details

2.7.2 Allergan Major Business

2.7.3 Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

2.7.4 Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Allergan Recent Developments and Future Plans

2.8 Shionogi

2.8.1 Shionogi Details

2.8.2 Shionogi Major Business

2.8.3 Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

2.8.4 Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Shionogi Recent Developments and Future Plans

2.9 Ligand Pharmaceuticals

2.9.1 Ligand Pharmaceuticals Details

2.9.2 Ligand Pharmaceuticals Major Business

2.9.3 Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

2.9.4 Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 Ligand Pharmaceuticals Recent Developments and Future Plans

2.10 Bayer

2.10.1 Bayer Details

2.10.2 Bayer Major Business

2.10.3 Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

2.10.4 Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 Bayer Recent Developments and Future Plans

2.11 Pantarhei Bioscience

2.11.1 Pantarhei Bioscience Details

2.11.2 Pantarhei Bioscience Major Business

2.11.3 Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

2.11.4 Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.11.5 Pantarhei Bioscience Recent Developments and Future Plans

2.12 Foamix Pharmaceuticals

2.12.1 Foamix Pharmaceuticals Details

2.12.2 Foamix Pharmaceuticals Major Business

2.12.3 Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

2.12.4 Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.12.5 Foamix Pharmaceuticals Recent Developments and Future Plans

2.13 Pep-Tonic Medical

2.13.1 Pep-Tonic Medical Details

2.13.2 Pep-Tonic Medical Major Business

2.13.3 Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

2.13.4 Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.13.5 Pep-Tonic Medical Recent Developments and Future Plans

2.14 Teva Pharmaceuticals

2.14.1 Teva Pharmaceuticals Details

2.14.2 Teva Pharmaceuticals Major Business

2.14.3 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

2.14.4 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.14.5 Teva Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 5 Postmenopausal Vaginal Atrophy (PVA) Treatment Players Market Share

3.2.2 Top 10 Postmenopausal Vaginal Atrophy (PVA) Treatment Players Market Share

3.2.3 Market Competition Trend

3.3 Postmenopausal Vaginal Atrophy (PVA) Treatment Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue and Market Share by Type (2016-2021)

4.2 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share by Application (2016-2021)

5.2 Postmenopausal Vaginal Atrophy (PVA) Treatment Market Forecast by Application (2021-2026)

6 North America

6.1 North America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast by Country (2016-2026)

6.2 United States

6.2.1 United States Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (2016-2026)

6.2.2 United States Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

6.2.3 United States Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

6.3 Canada

6.3.1 Canada Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

6.3.2 Canada Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

6.3.3 Canada Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

6.4 Mexico

6.4.1 Mexico Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

6.4.2 Mexico Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

6.4.3 Mexico Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

7 Europe

7.1 Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast by Country (2016-2026)

7.2 Germany

7.2.1 Germany Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

7.2.2 Germany Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

7.2.3 Germany Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

7.3 France

7.3.1 France Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

7.3.2 France Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

7.3.3 France Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

7.4 UK

7.4.1 UK Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

7.4.2 UK Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

7.4.3 UK Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

7.5 Russia

7.5.1 Russia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

7.5.2 Russia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

7.5.3 Russia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

7.6 Italy

7.6.1 Italy Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

7.6.2 Italy Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

7.6.3 Italy Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

7.7 Spain

7.7.1 Spain Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

7.7.2 Spain Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

7.7.3 Spain Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

7.8 Benelux

7.8.1 Benelux Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

7.8.2 Benelux Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

7.8.3 Benelux Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

7.9 Nordic

7.9.1 Nordic Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

7.9.2 Nordic Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

7.9.3 Nordic Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

8 Asia

8.1 Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast by Region (2016-2026)

8.2 China

8.2.1 China Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

8.2.2 China Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

8.2.3 China Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

8.3 Japan

8.3.1 Japan Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

8.3.2 Japan Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

8.3.3 Japan Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

8.4 South Korea

8.4.1 South Korea Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

8.4.2 South Korea Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

8.4.3 South Korea Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

8.5 India

8.5.1 India Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

8.5.2 India Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

8.5.3 India Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

8.6 Southeast Asia

8.6.1 Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

8.6.2 Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

8.6.3 Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

8.7 China Taiwan

8.7.1 China Taiwan Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

8.7.2 China Taiwan Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

8.7.3 China Taiwan Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

8.8 Australia

8.8.1 Australia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

8.8.2 Australia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

8.8.3 Australia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

9 South America

9.1 South America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast by Country (2016-2026)

9.2 Brazil

9.2.1 Brazil Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

9.2.2 Brazil Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

9.2.3 Brazil Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

9.3 Argentina

9.3.1 Argentina Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

9.3.2 Argentina Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

9.3.3 Argentina Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

10 MENA

10.1 MENA Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast by Region (2016-2026)

10.2 Saudi Arabia

10.2.1 Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

10.2.2 Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

10.2.3 Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

10.3 UAE

10.3.1 UAE Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

10.3.2 UAE Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

10.3.3 UAE Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

10.4 Turkey

10.4.1 Turkey Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size and Forecast (2016-2026)

10.4.2 Turkey Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Type (2016-2026)

10.4.3 Turkey Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size by Application (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million) by Region (2016-2021)

Table 5. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share by Region (2021-2026)

Table 6. EndoCeutics Corporate Information, Head Office, and Major Competitors

Table 7. EndoCeutics Major Business

Table 8. EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

Table 9. EndoCeutics Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Upsher-Smith Laboratories Corporate Information, Head Office, and Major Competitors

Table 11. Upsher-Smith Laboratories Major Business

Table 12. Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

Table 13. Upsher-Smith Laboratories Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. TherapeuticsMD Corporate Information, Head Office, and Major Competitors

Table 15. TherapeuticsMD Major Business

Table 16. TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

Table 17. TherapeuticsMD Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Bionovo Corporate Information, Head Office, and Major Competitors

Table 19. Bionovo Major Business

Table 20. Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

Table 21. Bionovo Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Pfizer Corporate Information, Head Office, and Major Competitors

Table 23. Pfizer Major Business

Table 24. Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

Table 25. Pfizer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. Novo Nordisk Corporate Information, Head Office, and Major Competitors

Table 27. Novo Nordisk Major Business

Table 28. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

Table 29. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Allergan Corporate Information, Head Office, and Major Competitors

Table 31. Allergan Major Business

Table 32. Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

Table 33. Allergan Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Shionogi Corporate Information, Head Office, and Major Competitors

Table 35. Shionogi Major Business

Table 36. Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

Table 37. Shionogi Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Ligand Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 39. Ligand Pharmaceuticals Major Business

Table 40. Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

Table 41. Ligand Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. Bayer Corporate Information, Head Office, and Major Competitors

Table 43. Bayer Major Business

Table 44. Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

Table 45. Bayer Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. Pantarhei Bioscience Corporate Information, Head Office, and Major Competitors

Table 47. Pantarhei Bioscience Major Business

Table 48. Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

Table 49. Pantarhei Bioscience Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 50. Foamix Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 51. Foamix Pharmaceuticals Major Business

Table 52. Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

Table 53. Foamix Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 54. Pep-Tonic Medical Corporate Information, Head Office, and Major Competitors

Table 55. Pep-Tonic Medical Major Business

Table 56. Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

Table 57. Pep-Tonic Medical Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 58. Teva Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 59. Teva Pharmaceuticals Major Business

Table 60. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Product and Solutions

Table 61. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 62. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million) by Players (2019-2021)

Table 63. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Share by Players (2019-2021)

Table 64. Breakdown of Postmenopausal Vaginal Atrophy (PVA) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)

Table 65. Postmenopausal Vaginal Atrophy (PVA) Treatment Players Head Office, Products and Services Provided

Table 66. Postmenopausal Vaginal Atrophy (PVA) Treatment Mergers & Acquisitions in the Past Five Years

Table 67. Postmenopausal Vaginal Atrophy (PVA) Treatment New Entrants and Expansion Plans

Table 68. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million) by Type (2016-2021)

Table 69. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Share by Type (2016-2021)

Table 70. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Forecast by Type (2021-2026)

Table 71. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue by Application (2016-2021)

Table 72. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Forecast by Application (2021-2026)

Table 73. North America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million) by Country (2016-2026)

Table 74. North America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Country (2016-2026)

Table 75. United States Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 76. United States Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Type (2016-2026)

Table 77. United States Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 78. United States Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 79. Canada Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 80. Canada Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Type (2016-2026)

Table 81. Canada Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 82. Canada Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 83. Mexico Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 84. Mexico Postmenopausal Vaginal Atrophy (PVA) Treatment Percentage Share Breakdown by Type (2016-2026)

Table 85. Mexico Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 86. Mexico Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 87. Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million) by Country (2016-2026)

Table 88. Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Country (2016-2026)

Table 89. Germany Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 90. Germany Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Type (2016-2026)

Table 91. Germany Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 92. Germany Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 93. France Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 94. France Postmenopausal Vaginal Atrophy (PVA) Treatment Percentage Share Breakdown by Type (2016-2026)

Table 95. France Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 96. France Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 97. UK Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 98. UK Postmenopausal Vaginal Atrophy (PVA) Treatment Percentage Share Breakdown by Type (2016-2026)

Table 99. UK Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 100. UK Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 101. Russia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 102. Russia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Type (2016-2026)

Table 103. Russia Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 104. Russia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 105. Italy Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 106. Italy Postmenopausal Vaginal Atrophy (PVA) Treatment Percentage Share Breakdown by Type (2016-2026)

Table 107. Italy Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 108. Italy Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 109. Spain Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 110. Spain Postmenopausal Vaginal Atrophy (PVA) Treatment Percentage Share Breakdown by Type (2016-2026)

Table 111. Spain Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 112. Spain Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 113. Benelux Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 114. Benelux Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Type (2016-2026)

Table 115. Benelux Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 116. Benelux Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 117. Nordic Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 118. Nordic Postmenopausal Vaginal Atrophy (PVA) Treatment Percentage Share Breakdown by Type (2016-2026)

Table 119. Nordic Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 120. Nordic Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 121. Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million) by Region (2016-2026)

Table 122. Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Region (2016-2026)

Table 123. China Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 124. China Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Type (2016-2026)

Table 125. China Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 126. China Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 127. Japan Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 128. Japan Postmenopausal Vaginal Atrophy (PVA) Treatment Percentage Share Breakdown by Type (2016-2026)

Table 129. Japan Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 130. Japan Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 131. South Korea Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 132. South Korea Postmenopausal Vaginal Atrophy (PVA) Treatment Percentage Share Breakdown by Type (2016-2026)

Table 133. South Korea Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 134. South Korea Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 135. India Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 136. India Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Type (2016-2026)

Table 137. India Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 138. India Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 139. Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 140. Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Percentage Share Breakdown by Type (2016-2026)

Table 141. Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 142. Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 143. China Taiwan Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 144. China Taiwan Postmenopausal Vaginal Atrophy (PVA) Treatment Percentage Share Breakdown by Type (2016-2026)

Table 145. China Taiwan Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 146. China Taiwan Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 147. Australia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 148. Australia Postmenopausal Vaginal Atrophy (PVA) Treatment Percentage Share Breakdown by Type (2016-2026)

Table 149. Australia Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 150. Australia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 151. South America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million) by Country (2016-2026)

Table 152. South America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Country (2016-2026)

Table 153. Brazil Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 154. Brazil Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Type (2016-2026)

Table 155. Brazil Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 156. Brazil Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 157. Argentina Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 158. Argentina Postmenopausal Vaginal Atrophy (PVA) Treatment Percentage Share Breakdown by Type (2016-2026)

Table 159. Argentina Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 160. Argentina Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 161. MENA Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million) by Country (2016-2026)

Table 162. MENA Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Country (2016-2026)

Table 163. Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 164. Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Type (2016-2026)

Table 165. Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 166. Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 167. UAE Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 168. UAE Postmenopausal Vaginal Atrophy (PVA) Treatment Percentage Share Breakdown by Type (2016-2026)

Table 169. UAE Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 170. UAE Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

Table 171. Turkey Postmenopausal Vaginal Atrophy (PVA) Treatment Market Growth Prospects (USD Million) by Type (2016-2026)

Table 172. Turkey Postmenopausal Vaginal Atrophy (PVA) Treatment Percentage Share Breakdown by Type (2016-2026)

Table 173. Turkey Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) by Application for the Period 2016-2026

Table 174. Turkey Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Analysis by Application (2016-2026)

List of Figures

Figure 1. Postmenopausal Vaginal Atrophy (PVA) Treatment Picture

Figure 2. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share by Type in 2020

Figure 3. Systemic Estrogen Treatments

Figure 4. Non-estrogenic Therapies

Figure 5. Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share by Application in 2020

Figure 6. Hospital Picture

Figure 7. Clinics Picture

Figure 8. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size, (USD Million): 2020 VS 2021 VS 2026

Figure 9. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue and Outlook (2016-2026) & (USD Million)

Figure 10. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share by Region (2016-2026)

Figure 11. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share by Region in 2020

Figure 12. North America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 13. Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 14. Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 15. South America Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 16. MENA Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 17. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Drivers

Figure 18. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Restraints

Figure 19. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Trends

Figure 20. EndoCeutics Recent Developments and Future Plans

Figure 21. Upsher-Smith Laboratories Recent Developments and Future Plans

Figure 22. TherapeuticsMD Recent Developments and Future Plans

Figure 23. Bionovo Recent Developments and Future Plans

Figure 24. Pfizer Recent Developments and Future Plans

Figure 25. Novo Nordisk Recent Developments and Future Plans

Figure 26. Allergan Recent Developments and Future Plans

Figure 27. Shionogi Recent Developments and Future Plans

Figure 28. Ligand Pharmaceuticals Recent Developments and Future Plans

Figure 29. Bayer Recent Developments and Future Plans

Figure 30. Pantarhei Bioscience Recent Developments and Future Plans

Figure 31. Foamix Pharmaceuticals Recent Developments and Future Plans

Figure 32. Pep-Tonic Medical Recent Developments and Future Plans

Figure 33. Teva Pharmaceuticals Recent Developments and Future Plans

Figure 34. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Share by Players in 2020

Figure 35. Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 36. Global Top 5 Players Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share in 2020

Figure 37. Global Top 10 Players Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Market Share in 2020

Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 39. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Share by Type in 2020

Figure 40. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Forecast by Type (2021-2026)

Figure 41. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Share by Application (2016-2021)

Figure 42. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue Share by Application in 2020

Figure 43. Global Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share Forecast by Application (2021-2026)

Figure 44. North America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Country (2016-2026)

Figure 45. United States Postmenopausal Vaginal Atrophy (PVA) Treatment Revenue (USD Million) and Forecast (2016-2026)

Figure 46. Canada Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 47. Postmenopausal Vaginal Atrophy (PVA) Treatment Market in Mexico: Recent Past, Current and Future Analysis (USD Million) and Forecast (2016-2026)

Figure 48. Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Country (2016-2026)

Figure 49. Europe Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Country in 2020

Figure 50. Germany Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 51. France Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 52. Postmenopausal Vaginal Atrophy (PVA) Treatment Market in UK: Recent Past, Current and Future Analysis (USD Million) and Forecast (2016-2026)

Figure 53. Russia Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 54. Italy Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 55. Postmenopausal Vaginal Atrophy (PVA) Treatment Market in Spain: Recent Past, Current and Future Analysis (USD Million) and Forecast (2016-2026)

Figure 56. Benelux Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 57. Nordic Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 58. Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size Share by Region (2016-2026)

Figure 59. Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size Share by Regions in 2020

Figure 60. China Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 61. Japan Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 62. Postmenopausal Vaginal Atrophy (PVA) Treatment Market in South Korea: Recent Past, Current and Future Analysis (USD Million) and Forecast (2016-2026)

Figure 63. India Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 64. Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 65. Postmenopausal Vaginal Atrophy (PVA) Treatment Market in China Taiwan: Recent Past, Current and Future Analysis (USD Million) and Forecast (2016-2026)

Figure 66. Postmenopausal Vaginal Atrophy (PVA) Treatment Market in Australia: Recent Past, Current and Future Analysis (USD Million) and Forecast (2016-2026)

Figure 67. South America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Country (2016-2026)

Figure 68. South America Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Country in 2020

Figure 69. Brazil Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 70. Argentina Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 71. MENA Postmenopausal Vaginal Atrophy (PVA) Treatment Market Share by Country (2016-2026)

Figure 72. MENA Postmenopausal Vaginal Atrophy (PVA) Treatment Market Size Share by Country in 2020

Figure 73. Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 74. UAE Postmenopausal Vaginal Atrophy (PVA) Treatment Estimates and Projections (USD Million) and Forecast (2016-2026)

Figure 75. Postmenopausal Vaginal Atrophy (PVA) Treatment Market in Turkey: Recent Past, Current and Future Analysis (USD Million) and Forecast (2016-2026)

Figure 76. Methodology

Figure 77. Research Process and Data Source